Merck Acquires Spero Therapeutics for $1.1 Billion

TL;DR

Merck is buying Spero for $1.1B cash, deal expected Q2 2024.

AI Summary

Spero Therapeutics, Inc. announced on March 29, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $1.1 billion in cash. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition by Merck, a major pharmaceutical company, signifies a significant consolidation in the antibiotic development space, potentially accelerating the availability of Spero's novel treatments for drug-resistant infections.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, and there's always a risk of regulatory hurdles or unforeseen issues that could delay or prevent the deal from closing.

Key Numbers

• $1.1B — Acquisition Price (Cash amount Merck is paying for Spero Therapeutics)
• Q2 2024 — Expected Closing (Anticipated timeframe for the acquisition to be finalized)

Key Players & Entities

• Spero Therapeutics, Inc. (company) — Company being acquired
• Merck & Co., Inc. (company) — Acquiring company
• $1.1 billion (dollar_amount) — Acquisition price
• March 29, 2024 (date) — Date of announcement
• second quarter of 2024 (date) — Expected closing period

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se

Filing Documents

• d818262d8k.htm (8-K) — 22KB
• 0001193125-24-082060.txt ( ) — 140KB
• spro-20240329.xsd (EX-101.SCH) — 3KB
• spro-20240329_lab.xml (EX-101.LAB) — 18KB
• spro-20240329_pre.xml (EX-101.PRE) — 11KB
• d818262d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 675 Massachusetts Avenue , 14 th Floor Cambridge , Massachusetts 02139 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (857) 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01 Other Events. Spero Therapeutics, Inc. (the "Company") expects to host its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on May 29, 2024. The Annual Meeting will be held entirely online. Information regarding how stockholders may attend, submit questions and vote online during the Annual Meeting will be set forth in the Company's definitive proxy statement for the Annual Meeting. This Annual Meeting is scheduled to occur more than 30 days in advance of the anniversary of last year's Annual Meeting of Stockholders held on October 5, 2023. This public disclosure constitutes notice of such scheduling pursuant to Section 1.10(b) of the Company's Amended and Restated Bylaws (the "Bylaws"). In order for a stockholder proposal under Rule 14a-8 or director nomination to be included in the proxy statement related to the Annual Meeting or otherwise to be properly brought before the Annual Meeting, stockholders are advised to review the Bylaws, which provide additional information regarding stockholder approvals and director nominations. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SPERO THERAPEUTICS, INC. Date: March 29, 2024 By: /s/ Esther Rajavelu Esther Rajavelu Chief Financial Officer, Chief Business Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR